Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
MNOV — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

0.44

Margin Of Safety %

Put/Call OI Ratio

0.34

EPS Next Q Diff

-0.01

EPS Last/This Y

-0.06

EPS This/Next Y

-0.11

Price

1.45

Target Price

9

Analyst Recom

1

Performance Q

4.35

Upside

-316.7%

Beta

0.66

Ticker: MNOV




17 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09MNOV1.380.360.0083
2026-03-10MNOV1.410.360.0083
2026-03-11MNOV1.430.370.0082
2026-03-12MNOV1.380.370.0082
2026-03-13MNOV1.380.370.0082
2026-03-17MNOV1.480.36999.9983
2026-03-18MNOV1.420.36999.9983
2026-03-20MNOV1.540.36999.9983
2026-03-25MNOV1.470.340.0082
2026-03-26MNOV1.420.340.0082
2026-03-27MNOV1.380.340.0082
2026-03-30MNOV1.370.340.0082
2026-03-31MNOV1.37N/AN/A0
2026-04-01MNOV1.430.340.0082
2026-04-06MNOV1.420.340.0082
2026-04-07MNOV1.420.340.0082
2026-04-08MNOV1.450.340.0082
DateSymbolLatestP/C OIP/C VolTotal OI
17 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09MNOV1.38-16.7- -0.32
2026-03-10MNOV1.41-16.7- -0.32
2026-03-11MNOV1.43-16.7- -0.32
2026-03-12MNOV1.38-16.7- -0.32
2026-03-13MNOV1.36-16.7- -0.32
2026-03-17MNOV1.49-16.7- -0.32
2026-03-18MNOV1.41-16.7-0.7-0.32
2026-03-19MNOV1.39-16.7-1.4-0.32
2026-03-20MNOV1.53-16.7-4.3-0.32
2026-03-23MNOV1.46-16.7-0.3-0.32
2026-03-24MNOV1.46-16.7-1.9-0.32
2026-03-25MNOV1.47-16.7-2.2-0.32
2026-03-26MNOV1.41-16.7-0.8-0.32
2026-03-27MNOV1.38-16.7-1.1-0.32
2026-03-30MNOV1.370.0-1.4-0.30
2026-03-31MNOV1.390.0-2.2-0.30
2026-04-01MNOV1.430.0-2.6-0.30
2026-04-02MNOV1.430.0-2.0-0.30
2026-04-06MNOV1.380.0-0.5-0.30
2026-04-07MNOV1.420.0-2.4-0.30
2026-04-08MNOV1.450.0-2.2-0.30
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09MNOV0.000.340.44
2026-03-10MNOV0.000.340.44
2026-03-11MNOV0.000.340.42
2026-03-12MNOV0.000.340.42
2026-03-13MNOV0.000.340.41
2026-03-18MNOV0.000.340.41
2026-03-19MNOV0.000.340.41
2026-03-20MNOV0.000.340.41
2026-03-23MNOV0.000.340.41
2026-03-24MNOV0.000.340.41
2026-03-25MNOV0.000.340.44
2026-03-26MNOV0.000.340.44
2026-03-27MNOV0.000.340.44
2026-03-30MNOV0.000.340.44
2026-03-31MNOV0.000.340.44
2026-04-01MNOV0.000.340.44
2026-04-02MNOV0.000.340.44
2026-04-06MNOV0.000.340.44
2026-04-07MNOV0.000.340.44
2026-04-08MNOV0.000.340.44
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.05

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

Institutional Transactions

0.34

Beta

0.66

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

27

Growth Score

24

Sentiment Score

96

Actual DrawDown %

71.5

Max Drawdown 5-Year %

-76.7

Target Price

9

P/E

Forward P/E

PEG

P/S

172.86

P/B

1.7

P/Free Cash Flow

EPS

-0.24

Average EPS Est. Cur. Y​

-0.3

EPS Next Y. (Est.)

-0.41

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2928.78

Relative Volume

0.46

Return on Equity vs Sector %

-56.1

Return on Equity vs Industry %

-39.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

-2.2
MNOV Healthcare
$1.44
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
8/20
Pullback
11/25
Volume
11/15
Valuation
12/20
TP/AR
2/10
Options
8/10
RSI
50.5
Range 1M
56.2%
Sup Dist
2.5%
🚀
Momentum Growth
Ride accelerating trends
N/A
21 /100
WEAK
Momentum
2/25
Growth
9/30
Estimates
0/20
Inst/Vol
4/15
Options
6/10
EPS Yr
-27.1%
EPS NY
-31.2%
52W%
35.6%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +525% upside
Quality
2/30
Valuation
16/30
Growth
5/25
Stability
7/10
LT Trend
2/5
Upside
+525%
Quality
27
MediciNova, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 6
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
MNOV

Latest News

Caricamento notizie per MNOV
stock quote shares MNOV – Medicinova Inc Stock Price stock today
news today MNOV – Medicinova Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MNOV – Medicinova Inc yahoo finance google finance
stock history MNOV – Medicinova Inc invest stock market
stock prices MNOV premarket after hours
ticker MNOV fair value insiders trading